Exosome In Vivo Efficacy & Safety Evaluation

Q: What animal species do you support for studies?

Our standard in vivo platform uses mice (BALB/c, C57BL/6J, ICR) and rats (Sprague-Dawley). For specialized needs, we can arrange studies in additional species including hamsters, guinea pigs, and zebrafish through partner facilities.

Q: Can you conduct GLP-compliant toxicology studies?

Our standard in vivo services are research-grade (non-GLP) with validated methods and comprehensive documentation. GLP-compliant 14-day and 28-day repeated-dose toxicology studies, including GLP-compliant clinical pathology, histopathology by board-certified pathologists, and audited data packages, are available as custom services with extended timelines. Contact us to discuss your specific regulatory requirements.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide comprehensive in vivo efficacy and safety evaluation services purpose-built for microbial extracellular vesicles (mEVs), including bacterial outer membrane vesicles (OMVs), membrane vesicles (MVs) from Gram-positive bacteria, fungal EVs, and phage-derived vesicles. Our platform integrates pharmacokinetic and biodistribution studies, therapeutic efficacy evaluation in disease models, immunogenicity and tolerability assessment, repeated-dose toxicology, and organ-specific histopathological analysis into a single, milestone-driven workflow that bridges the gap between in vitro functional validation and IND-enabling preclinical packages.

Unlike generic preclinical CROs that apply small-molecule or biologic testing frameworks to microbial vesicles without adaptation, we have optimized every animal model, dosing regimen, tissue collection protocol, and analytical endpoint for the unique pharmacology, biodistribution kinetics, and immunological properties of microbial vesicles. From single-dose pilot PK studies to GLP-compliant repeated-dose toxicology, clients receive publication-quality efficacy data, comprehensive safety dossiers, and regulatory-ready documentation that support CMC packages, IND submissions, and product development decisions. Contact us to discuss your in vivo evaluation strategy.

Scientific schematic of integrated in vivo efficacy and safety evaluation platform for microbial extracellular vesicles, showing pharmacokinetic biodistribution, disease model efficacy, immunogenicity assessment, toxicology, and histopathology modules connected in an ecosystem scene with mouse models.
Figure 1. Schematic overview of the integrated in vivo efficacy and safety evaluation platform for microbial extracellular vesicles, spanning pharmacokinetic and biodistribution studies, therapeutic efficacy evaluation, immunogenicity assessment, repeated-dose toxicology, and organ-specific histopathological analysis.

Services

Service Workflow

Commercial end-to-end service workflow diagram for in vivo efficacy and safety evaluation showing seven stages from study design through animal model selection, dose administration, sample collection, endpoint analysis, histopathology, and final regulatory-ready report delivery.

Inquiry

Service Details

Split-screen comparison showing a mouse silhouette on the left with fluorescent-labeled vesicle distribution heatmap across organs, and a right panel with plasma concentration-time curve plots and tissue biodistribution bar charts.

Pharmacokinetic & Biodistribution Studies

We provide comprehensive pharmacokinetic and biodistribution evaluation services for mEVs across multiple administration routes. Our capabilities include plasma concentration-time profiling, tissue biodistribution quantification across major organs, excretion profiling, and non-compartmental PK parameter calculation. Clients receive complete PK reports with C_max, T_max, AUC, half-life, clearance, and volume of distribution, along with organ-specific biodistribution data and dosing rationale recommendations that support IND pharmacology sections.

Macroscopic biological scene showing a mouse with DSS-induced colitis model, surrounded by clinical endpoints including colon length measurement, histopathology scoring, body weight tracking, and disease activity index monitoring.

Disease Model Efficacy Evaluation

We offer therapeutic efficacy evaluation across gastrointestinal, immunological, oncological, and dermatological disease model portfolios. Our service delivers disease-specific endpoint quantification including clinical scoring, biomarker profiling, immune cell analysis, tumor growth monitoring, and histopathological assessment. Clients receive preclinical proof-of-concept efficacy reports with dose-response analysis, statistical comparison against positive controls, and integrated data packages suitable for investor presentations and regulatory submissions.

Molecular close-up illustration showing anti-mEV antibody titers represented as Y-shaped immunoglobulins binding to vesicle surface antigens, with T cell activation markers (CD4, CD8) and cytokine storm indicators (IL-6, TNF-alpha) visualized as signaling cascades.

Immunogenicity & Tolerability Assessment

We provide immunogenicity and tolerability assessment services that identify safety risks specific to microbial vesicles. Our capabilities include antibody response profiling, cytokine release evaluation, immune cell subset analysis, innate immune activation profiling (PAMP-mediated TLR signaling), and acute tolerability monitoring. Clients receive comprehensive immunogenicity risk reports with antibody titer kinetics, cellular and innate immune response data, and clinical chemistry profiles that support safety characterization and risk mitigation strategies for therapeutic mEV products.

3D product rendering of a toxicology study design showing dose groups arranged as vials with concentration gradients, surrounded by clinical pathology panels including hematology analyzer, serum chemistry analyzer, and organ weight balance.

Repeated-Dose Toxicology & Safety Evaluation

We conduct repeated-dose toxicology studies with ICH-aligned study designs and GLP-compliant documentation. Our service covers clinical observation, body weight monitoring, clinical pathology, organ weight assessment, gross necropsy, and comprehensive histopathological examination. Clients receive core safety data packages including NOAEL and NOEL determination with benchmark dose modeling, board-certified veterinary pathology review, and audited toxicology reports suitable for IND-enabling submissions.

Microscopy-style artistic rendering showing tissue sections of liver, kidney, spleen, and lung with H&E staining patterns, inflammatory cell infiltration markers, and tissue architecture integrity indicators.

Organ-Specific Histopathological Analysis

We provide organ-specific histopathological evaluation services with emphasis on mEV-target organs identified by biodistribution studies. Our capabilities include standard tissue panel assessment, specialized immunohistochemistry for barrier integrity markers, inflammatory scoring, and quantitative morphometry. All evaluations are performed under board-certified veterinary pathology review with digital slide documentation. Clients receive comprehensive histopathology reports with semi-quantitative scoring, target organ toxicity identification, and mechanistic safety assessment that supports regulatory submissions.

Service Specifications & QC Standards

Animal Models & Species

Primary species: BALB/c mice, C57BL/6J mice, ICR mice, Sprague-Dawley rats.
Disease models: DSS-induced colitis, TNBS-induced colitis, LPS-induced sepsis, OVA-induced asthma, B16-F10 melanoma, CT26 colon carcinoma, imiquimod-induced psoriasis.
Age range: Young adult mice (typically 6–10 weeks), customizable based on study design.
Group size: Statistically powered cohorts tailored to study objectives and regulatory requirements.

Instrumentation & Capability

In Vivo Imaging: Fluorescent and bioluminescent imaging for real-time biodistribution tracking.
Clinical Pathology: Automated hematology and serum chemistry analysis for blood and biochemical profiling.
Cytokine Profiling: Multiplex bead array and ELISA-based platforms for cytokine quantification.
Flow Cytometry: Multi-parameter immunophenotyping for immune subset analysis.
Histopathology: Digital slide scanning with board-certified pathology review.
PK Analysis: Non-compartmental and compartmental pharmacokinetic modeling.
Tissue Processing: Standardized homogenization and vesicle recovery for biodistribution samples.

Typical Data Range

IV mEV half-life: 30 min to 4 h (size and strain dependent).
Oral bioavailability: Highly variable; enhanced by enteric coating and formulation optimization.
Major accumulation organs: liver, spleen, lung, kidneys (IV route).
Efficacy range: 20–70% reduction in disease activity index (DSS colitis model).
Anti-mEV IgG seroconversion: detectable at day 14, peak at day 28 (strain dependent).
NOAEL: Determined empirically per strain and route; mEV-specific toxicology data remain limited in literature.

Turnaround Time

Project Type	Timeline
Single-dose PK/biodistribution study	3–4 weeks
Disease model efficacy study (single model)	4–6 weeks
Immunogenicity assessment (28-day)	5–6 weeks
14-day repeated-dose toxicology	6–8 weeks
28-day repeated-dose toxicology	10–14 weeks
Comprehensive preclinical package (PK + efficacy + tox)	16–24 weeks

Timeline may vary based on model complexity, group size, and histopathology load.

Deliverables

PK study report: Plasma concentration-time curves, PK parameters, tissue biodistribution tables, excretion data.
Efficacy study report: Disease endpoint data, statistical analysis, dose-response curves, histopathology images.
Immunogenicity report: Antibody titer kinetics, ELISpot data, T cell subset profiles, tolerability summary.
Toxicology report: Clinical pathology data, organ weight tables, histopathology findings with images, NOAEL/NOEL determination.
Integrated preclinical summary: Cross-study correlation, risk assessment, IND-pharmacology and toxicology summary sections.

Quality Control

Test article characterization: NTA, DLS, protein content, endotoxin (LAL), and sterility testing on every batch before dosing.
Vehicle controls: Sterile PBS or formulation-matched vehicle for every study arm.
Positive controls: Dexamethasone (anti-inflammatory), 5-FU (anti-tumor), LPS (immunogenicity).
Randomization and blinding: Animals randomized by body weight; endpoint assessors blinded to treatment groups.
Data integrity: GLP-compliant data management, audit trail, and electronic signatures available.
Compliance checklist for minimal characterization requirements aligned with industry guidelines for extracellular vesicle studies.

Sample Requirements

Required Information	Optional Information	Not Accepted
Sample type (OMVs, CMVs, fungal EVs, phage vesicles) Purified vesicle suspension in sterile buffer Particle concentration (NTA-derived) Protein concentration (BCA/Bradford) Endotoxin level (LAL assay result) Sterility test result Storage buffer composition and pH Species and strain identification	Prior in vitro functional data Intended clinical administration route Target disease indication Desired dose range or dosing regimen GLP vs. research-grade study design Specific safety concerns or risk factors Regulatory submission timeline	Samples with visible contamination (turbidity, precipitation) Endotoxin >10 EU/mg protein (without prior discussion; threshold may vary by mEV type and application) Samples failing sterility test Intact bacterial or fungal cell cultures Samples in organic solvents or non-physiological buffers Samples shipped without cold-chain documentation

Recommended Sample Quantity by Study:

Study Type	Minimum Quantity	Recommended Quantity
Pilot PK (single dose, multiple timepoints)	0.5–1 mg total protein	1–2 mg total protein
Full PK/biodistribution (multiple timepoints)	2–5 mg total protein	5–10 mg total protein
Efficacy study (single model)	5–10 mg total protein	10–20 mg total protein
Immunogenicity (28-day)	10–20 mg total protein	20–40 mg total protein
14-day toxicology	20–40 mg total protein	40–80 mg total protein
28-day toxicology	40–80 mg total protein	80–160 mg total protein

Storage & Shipping: Ship purified vesicle suspensions on dry ice (–80°C) with cold-chain documentation and temperature logger. Avoid repeated freeze-thaw cycles (max 2 cycles). Recommended buffer: sterile, endotoxin-free PBS. For oral administration studies, provide sterility and endotoxin documentation. Include certificate of analysis if available.

Inquiry

Our Advantages

mEV-Specific PK Methodology: Our pharmacokinetic protocols are specifically designed for microbial vesicle kinetics, including vesicle-specific labeling strategies, tissue extraction methods optimized for nano-sized particles, and correction factors for vesicle stability in biological matrices that small-molecule PK approaches cannot capture.
Validated Disease Model Portfolio: Our efficacy models span gastrointestinal, immunological, oncological, and dermatological indications with validated endpoints, scoring criteria, and positive controls, enabling head-to-head efficacy comparison of mEV candidates against clinical standards of care.
Immunogenicity Risk Identification: Our anti-mEV antibody profiling, splenocyte recall assays, and T cell subset analysis identify immunogenicity risks specific to microbial vesicles that standard biologics immunogenicity frameworks may not detect, such as LPS-mediated TLR4 activation (OMVs) or LTA-dependent TLR2 signaling (Gram-positive MVs).
Regulatory-Ready Study Design: Our toxicology study designs follow ICH M3(R2) recommendations with GLP-compliant documentation, IACUC ethical oversight, and report formats suitable for IND pharmacology and toxicology summary sections.
Integrated Preclinical Packages: We combine PK, efficacy, immunogenicity, and toxicology data into a unified preclinical summary that aligns with regulatory submission requirements, reducing the need for clients to coordinate across multiple CROs.

Applications

Scene-based storytelling showing a mouse gut lumen with probiotic vesicles reducing inflammation, restoring mucus layer, and rebalancing microbiota in an inflammatory bowel disease context.

Probiotic mEV IBD Efficacy Proof-of-Concept

In vivo colitis models validate probiotic vesicle therapeutic efficacy for inflammatory bowel disease.

Central focus composition with OMV vaccine adjuvant particle surrounded by immune activation modules, antibody titer indicators, and safety checkmark symbols.

OMV Vaccine Adjuvant Safety Profiling

Immunogenicity and toxicology studies ensure OMV adjuvant safety for vaccine development.

Left-to-right narrative flow from mEV production through PK/biodistribution, efficacy in disease model, toxicology safety, to IND submission document.

Therapeutic mEV IND-Enabling Preclinical

Integrated PK, efficacy, and toxicology data packages support IND submissions for therapeutic mEV candidates.

Scale transition from skin surface application site down to tissue-level safety evaluation showing skin irritation, sensitization, and histopathology assessment.

Cosmetic mEV Topical Safety Assessment

Dermal tolerability and histopathology validate cosmetic vesicle safety for topical applications.

Case Study

Case Study: Lactobacillus plantarum Q7-Derived Extracellular Vesicles Ameliorate DSS-Induced Ulcerative Colitis in Mice

Researchers evaluated the therapeutic efficacy of Lactobacillus plantarum Q7-derived extracellular vesicles (Q7-EVs) in a DSS-induced ulcerative colitis model using C57BL/6J mice. Oral administration of Q7-EVs (0.5 mg/kg and 1.0 mg/kg) significantly attenuated colitis severity, as evidenced by improved body weight, reduced disease activity index, and preserved colon length compared to DSS-only controls.

Histopathological analysis confirmed attenuated colonic tissue damage and reduced inflammatory cell infiltration. Cytokine analysis demonstrated significant suppression of IL-6, IL-1β, TNF-α, and IL-2 in colon tissue, with corresponding reductions in serum IL-6, IL-1β, and TNF-α levels. 16S rRNA sequencing revealed that Q7-EVs modulated gut microbiota composition by increasing Bifidobacterium and Muribaculaceae while reducing pro-inflammatory Proteobacteria. This study demonstrates that in vivo efficacy models can validate the therapeutic potential of probiotic-derived mEVs and provide preclinical evidence supporting gut-targeted product development.

Figure 2. The effect of Q7-EVs on DSS-induced colitis in C57BL/6J mice. (Hao, et al. 2021)

FAQs

Q: What animal species do you support for in vivo studies?

A: Our standard in vivo platform uses mice (BALB/c, C57BL/6J, ICR) and rats (Sprague-Dawley). For specialized needs, we can arrange studies in additional species including hamsters, guinea pigs, and zebrafish through partner facilities.

Q: How do you label mEVs for in vivo tracking?

A: We use three complementary labeling strategies: (1) lipophilic membrane dyes (DiR, PKH67) for fluorescent imaging via IVIS; (2) radionuclide labeling (¹¹¹In) for quantitative gamma counting; and (3) genetic labeling with reporter proteins or nucleic acid cargo tracking via qPCR for tissue recovery quantification. Each method is validated for labeling efficiency (≥90%), vesicle integrity retention (NTA/DLS pre- and post-labeling), and signal stability over the study duration.

Q: Can you conduct GLP-compliant toxicology studies?

A: Our standard in vivo services are research-grade (non-GLP) with validated methods and comprehensive documentation. GLP-compliant 14-day and 28-day repeated-dose toxicology studies, including GLP-compliant clinical pathology, histopathology by board-certified pathologists, and audited data packages, are available as custom services with extended timelines. Contact us to discuss your specific regulatory requirements.

Q: How is mEV immunogenicity different from standard biologic immunogenicity?

A: Microbial vesicles carry PAMPs that vary by source: OMVs contain lipopolysaccharide (LPS) activating TLR4, while Gram-positive MVs carry lipoteichoic acid (LTA), peptidoglycan fragments, and lipoproteins activating TLR2 and NOD2. These innate immune activations occur independently of adaptive anti-vesicle antibody responses. Our immunogenicity assessment covers both innate PAMP-mediated activation and adaptive anti-vesicle antibody responses, providing a comprehensive safety profile not captured by standard biologics immunogenicity frameworks.

Q: What is the minimum sample quantity needed for a pilot PK study?

A: A pilot PK study typically requires 0.5–1 mg of total vesicle protein, depending on administration route, detection method, and analytical sensitivity. A full PK/biodistribution study requires 2–5 mg. We recommend providing 2× the estimated dose to account for formulation losses and stability testing.

Q: Do you offer oral administration studies for probiotic vesicles?

A: Yes. Oral gavage is our primary administration route for probiotic-derived mEVs targeting gastrointestinal applications. We assess gastric stability, intestinal barrier absorption, fecal recovery, and tissue biodistribution following oral delivery. Enteric-coated formulations and encapsulation strategies to enhance bioavailability can be evaluated as custom services.

Q: How long does it take to complete a comprehensive preclinical package?

A: A comprehensive preclinical package (single-dose PK, disease model efficacy, 28-day repeated-dose toxicology) typically requires 16–24 weeks from study initiation to final report. Staggered study start dates allow overlapping timelines to compress overall duration.

References:

Hao, H., et al. (2021). Effect of Extracellular Vesicles Derived From Lactobacillus plantarum Q7 on Gut Microbiota and Ulcerative Colitis in Mice. Frontiers in Immunology, 12, 777147.

Services

Inquiry